Polaris Group announced appointment of Hung-Wen Chena as CEO in place of Shaw Chen, due After achieving successful clinical milestone with MPM, Dr. Shaw Chen's position will be adjusted to an executive advisor to instruct the clinical trials and the application of new drug for the Company. Effective November 11, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
72 TWD | +0.98% | +5.26% | -4.76% |
05-15 | Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA | CI |
05-14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.76% | 1.65B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- 6550 Stock
- News Polaris Group
- Polaris Group Announces CEO Changes